Elizabeth Warren, a U.S. Senator, questioned Federal Reserve Chair Kevin Waller about the source of the $100 million he received just before taking office, criticizing it as "encouraging corruption." During a Senate Banking Committee hearing on the 17th, Senator Warren asked, "Who gave you the $100 million?" However, Waller did not disclose the source of the payment. Warren pointed out, "The atmosphere you are creating seems to invite corruption." Additionally, she criticized Waller for not directly addressing the issue of Fed Vice Chair Michelle Bowman attending an unofficial Wall Street dinner during the official "blackout period." Warren warned that World Liberty Financial (WLFI), a cryptocurrency business owned by the Trump family, is seeking to raise about $1.4 billion by 2025 and is applying for a banking license, suggesting that political influence could affect the Fed. Waller has previously mentioned Bitcoin as an important asset, showing a favorable stance towards cryptocurrencies. The possibility of interest rate hikes is also increasing, with the CME FedWatch Tool indicating a 59% chance of a hike in October and a 73.4% chance of a subsequent hike in December. This dispute intertwines the Fed's independence, Trump's cryptocurrency business, and interest rate forecasts, suggesting that as political pressure increases, the debate will intensify.
This content is provided for general informational purposes only and doesn't constitute financial, investment, legal, or tax advice. Any events, rewards, online promotions, or related information mentioned herein should not be considered a recommendation, solicitation, or invitation to purchase, sell, trade, or otherwise deal in any crypto assets. Crypto assets are highly volatile and may result in loss. The availability of WEEX services, products, and related events may vary by region. You are responsible for ensuring that your participation is in accordance with applicable local laws and regulations.

























Moderna shares more than doubled on 19 August 2026 after Merck and Moderna said the Phase 3 INTerpath-001 trial of intismeran autogene plus KEYTRUDA met its recurrence-free survival endpoint in resected melanoma. This page explains what the result is, why the stock reacted this hard, what is still unknown, which dates come next (presentation and earnings, both unconfirmed), and what a trader can actually do on WEEX — which does not list Moderna; the nearest instrument is the XBI-USDT biotech ETF perpetual. No price targets, no forecasts.




